Tag Archives: Merck

With ‘evolved’ treatment landscape, Merck pulls Keytruda’s FDA nod in third-line stomach cancer

Two months after a key FDA panel voted down Merck’s conditional nod for Keytruda as a third-line treatment for certain stomach cancer patients, the company says it’s pulling the plug on the indication.  Following consultation with the FDA, Merck on Thursday said it will voluntarily withdraw its U.S. accelerated approval for Keytruda as a third-line… Read More »

ADA: Merck, Pfizer’s Steglatro rings up CV safety win, but it still lags heart-helping peers

Merck and Pfizer’s Steglatro, late the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But it’s cardiovascular outcomes data won’t help it get on their level. Steglatro showed it could match placebo when it comes to the combined rate of heart attack, stroke and cardiovascular death… Read More »